General Information of DTT (ID: TTRK8B9)

DTT Name Sodium channel unspecific (NaC) DTT Info
Gene Name NaC

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
18 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Benzocaine DMI18HW Anaesthesia 9A78.6 Approved [1]
Butacaine DM584TM Pain MG30-MG3Z Approved [2]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [3]
Eslicarbazepine DMZREFQ Seizure disorder 8A6Z Approved [4]
Levobupivacaine DM783CH Anaesthesia 9A78.6 Approved [5]
LIDOFLAZINE DMV23GL Angina pectoris BA40 Approved [6]
LOMERIZINE DME0TC8 Migraine 8A80 Approved [7]
Mepivacaine DMH2NMY Analgesia MB40.8 Approved [5]
Oxybuprocaine DMI0GDH Anaesthesia 9A78.6 Approved [8]
Pachycarpine DMNKT8Z Postpartum haemorrhage JA43 Approved [9]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [10]
Phenacemide DMOHS9P Epilepsy 8A60-8A68 Approved [11]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [12]
Pilsicainide DMZ65K8 Heart arrhythmia BC65 Approved [13]
Pirmenol DMBCYF5 Heart arrhythmia BC65 Approved [14]
Rufinamide DMWE60C Epilepsy 8A60-8A68 Approved [15]
Tetrodotoxin DMWMPRG Bacterial infection 1A00-1C4Z Approved [16]
Zonisamide DM0DTF7 Alcohol dependence 6C40.2 Approved [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Approved Drug(s)
16 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Carisbamate DM4Y1SP Epilepsy 8A60-8A68 Phase 3 [4]
Ralfinamide DMUNMY0 Neuropathic pain 8E43.0 Phase 3 [18]
ATI-2042 DMWP59B Atrial fibrillation BC81.3 Phase 2 [19]
BN82451 DMUM2KA Parkinson disease 8A00.0 Phase 2 [20]
COL-1077 DMNC76I Pain MG30-MG3Z Phase 2 [21]
Crobenetine DM85WID Pain MG30-MG3Z Phase 2 [22]
GSK2339345 DMRA3T2 Cough MD12 Phase 2 [23]
HBI-3000 DM74ZKN Heart arrhythmia BC65 Phase 2 [24]
NS-7 DM3H82Q Nerve injury ND56.4 Phase 2 [25]
NW-3509 DM2UJ1H Schizophrenia 6A20 Phase 2 [26]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [27]
SMP-986 DMTJOQX Overactive bladder GC50.0 Phase 2 [28]
P-552-02 DM6V5OB Cystic fibrosis CA25 Phase 1/2 [29]
ADCI DM59EUY Epileptic seizures 8A61-8A6Z Phase 1 [30]
AZD-3161 DMICW7D Peripheral neuropathy 8C0Z Phase 1 [31]
BDD-10103 DMGAP53 Pain MG30-MG3Z Phase 1 [32]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Clinical Trial Drug(s)
35 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
LUBELUZOLE DMFGMD9 Neurological disorder 6B60 Discontinued in Preregistration [7]
Bidisomide DM47ZHW Heart arrhythmia BC65 Discontinued in Phase 3 [33]
Licarbazepine DMWUS8N Bipolar disorder 6A60 Discontinued in Phase 3 [34]
4030W92 DMQV4C3 Pain MG30-MG3Z Discontinued in Phase 2 [35]
4991W93 DMUXMGN Migraine 8A80 Discontinued in Phase 2 [36]
534U87 DMYOG98 Epileptic seizures 8A61-8A6Z Discontinued in Phase 2 [37]
Levosemotiadil DMKSY2R Cardiac arrhythmias BC9Z Discontinued in Phase 2 [38]
Org-7797 DMU5PFD Cardiac arrhythmias BC9Z Discontinued in Phase 2 [39]
Pentisomide DMTGBPW Heart arrhythmia BC65 Discontinued in Phase 2 [40]
Pyrazinoylguanidine DMD308S Diabetic complication 5A2Y Discontinued in Phase 2 [41]
RSD-921 DMIKUXN Anaesthesia 9A78.6 Discontinued in Phase 2 [42]
SILPERISONE HYDROCHLORIDE DMY30G2 Spasm MB47.3 Discontinued in Phase 2 [43]
SIPATRIGINE DMMQ4GC Neurological disorder 6B60 Discontinued in Phase 2 [7]
SOLPECAINOL HYDROCHLORIDE DMHITR4 Cardiac arrhythmias BC9Z Discontinued in Phase 2 [44]
AMELTOLIDE DMALVX2 Epileptic seizures 8A61-8A6Z Discontinued in Phase 1 [45]
Artilide DMJDYBX Cardiac arrhythmias BC9Z Discontinued in Phase 1 [46]
AWD-140-190 DMTG9EZ Epileptic seizures 8A61-8A6Z Discontinued in Phase 1 [47]
SL-90.0571 DMFUTHB Epilepsy 8A60-8A68 Discontinued in Phase 1 [48]
A-76895 DMTF6D9 Epilepsy 8A60-8A68 Terminated [49]
AM-66 DMGBT63 Pain MG30-MG3Z Terminated [49]
BDF-9148 DMV5K0I Cardiac failure BD10-BD13 Terminated [50]
Berlafenone DMQA4JU Heart arrhythmia BC65 Terminated [48]
BW-1003C87 DMEP9B6 Cerebrovascular ischaemia 8B1Z Terminated [51]
DPI-201-106 DM1AQVE Cardiovascular disease BA00-BE2Z Terminated [52]
E-2070 DMAU0FP Neuropathic pain 8E43.0 Terminated [53]
GE-68 DMZF9CY Heart arrhythmia BC65 Terminated [54]
PD-85639 DMNUKB4 N. A. N. A. Terminated [7]
R-59494 DM36JFP Ischemia 8B10-8B11 Terminated [55]
Ralitoline DM7HAE9 Epilepsy 8A60-8A68 Terminated [56]
Recainam DMDC2E8 Heart arrhythmia BC65 Terminated [57]
RP-66055 DM09QLY Cerebral infarction 8B11.5Z Terminated [58]
RS-2135 DMFJ0KC Heart arrhythmia BC65 Terminated [59]
SRSC-355 DMFLPU5 Neuropathic pain 8E43.0 Terminated [60]
U-54494A DM4WUEP Epilepsy 8A60-8A68 Terminated [61]
U-92032 DMTYO3P N. A. N. A. Terminated [62]
------------------------------------------------------------------------------------
⏷ Show the Full List of 35 Discontinued Drug(s)
15 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole DMR0HDF Discovery agent N.A. Investigative [63]
2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole DM94PBL Discovery agent N.A. Investigative [63]
2-Hydroxy-2-phenyl-nonanoic acid amide DM2GPF6 Discovery agent N.A. Investigative [64]
4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole DML6PTX Discovery agent N.A. Investigative [63]
4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole DM2I13S Discovery agent N.A. Investigative [63]
4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole DMLSUXD Discovery agent N.A. Investigative [63]
4-Biphenyl-4-yl-2-hexyl-1H-imidazole DMPIH4L Discovery agent N.A. Investigative [63]
4-Biphenyl-4-yl-2-methyl-1H-imidazole DMNLC2Y Discovery agent N.A. Investigative [63]
5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione DMYD8GP Discovery agent N.A. Investigative [65]
5-Heptyl-5-phenyl-imidazolidine-2,4-dione DMICKOU Discovery agent N.A. Investigative [64]
5-Hexyl-5-phenyl-imidazolidine-2,4-dione DMCDUO1 Discovery agent N.A. Investigative [64]
5-Nonyl-5-phenyl-imidazolidine-2,4-dione DM2DWUQ Discovery agent N.A. Investigative [64]
BW-202W92 DMFKXMT Discovery agent N.A. Investigative [66]
L-741742 DMP75YK Discovery agent N.A. Investigative [67]
Saxitoxin DMLX8RW Discovery agent N.A. Investigative [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94.
2 WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
3 Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
4 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
5 Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
6 Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
7 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
8 Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53.
9 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
10 In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
11 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
12 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
13 A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med. 2011;225(1):35-42.
14 Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):462-71.
15 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
18 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
21 Clinical pipeline report, company report or official report of Columbia Laboratories.
22 Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8.
23 ClinicalTrials.gov (NCT01494636) The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects. U.S. National Institutes of Health.
24 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
25 Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: A possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther. 2000 May;293(2):522-9.
26 Clinical pipeline report, company report or official report of Newron.
27 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
28 DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129.
29 US patent application no. 2014,0221,286, Sodium channel blockers reduce glucagon secretion.
30 The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
31 Recent progress in sodium channel modulators for pain.Bioorganic & Medicinal Chemistry Letters Volume 24, Issue 16, 15 August 2014, Pages 3690-3699.
32 Clinical pipeline report, company report or official report of Birds Pharma AG.
33 Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. Clin Pharmacol Ther. 1992 Apr;51(4):371-8.
34 Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
35 Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model. Pharmacol Biochem Behav. 2004 Jun;78(2):349-55.
36 CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010 Oct;6(10):573-82.
37 The anticonvulsant BW534U87 depresses epileptiform activity in rat hippocampal slices by an adenosine-dependent mechanism and through inhibition of voltage-gated Na+ channels. Br J Pharmacol. 1999 Nov;128(5):1011-20.
38 Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33.
39 Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. J Cardiovasc Pharmacol. 1989 Aug;14(2):205-12.
40 Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro. Drugs Exp Clin Res. 1995;21(4):145-51.
41 Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem. 2006 Jul 13;49(14):4098-115.
42 Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921. Br J Pharmacol. 1999 May;127(1):9-18.
43 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
44 US patent application no. 2002,0102,217, Diagnostic,therapeutic agents.
45 Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsant. J Med Chem. 1991 Apr;34(4):1253-7.
46 Potassium channel blockers as antiarrhythmic drugs. Drug Development Research Volume 33, Issue 3, pages 235-249, November 1994.
47 Effects of AWD 140-190 on stimulus-induced field potentials and on different patterns of epileptiform activity induced by low calcium or low magnesium in rat entorhinal cortex hippocampal slices. Epilepsy Res. 1997 Dec;29(1):59-69.
48 WO patent application no. 19990639849, Novel sodium channel drugs and uses.
49 CA patent application no. 849505, Sodium channel blockers reduce glucagon secretion.
50 The relaxing effect of BDF 9148 on the KCl-contracted aorta isolated from normo- and hyper-tensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Feb;357(2):126-32.
51 The pyrimidine-derivative, BW1003C87, protects CA1 and striatal neurons following transient severe forebrain ischaemia in rats. A microdialysis and histological study. Neuroscience. 1993 Sep;56(1):93-9.
52 Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17-24.
53 Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108.
54 Electrophysiological properties of the propafenone-analogue GE 68 (1-[3-(phenylethyl)-2-benzofuryl]-2-(propylamino)-ethanol) in isolated preparations and ventricular myocytes of guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1997 Feb;355(2):230-8.
55 Veratridine activates a silent sodium channel in rat isolated aorta. Eur J Pharmacol. 1992 Aug 25;219(2):253-9.
56 Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):442-52.
57 Effects of renal function on recainam pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1995 May;57(5):492-8.
58 Synthesis, anticonvulsant and neuroprotective activities of RP 66055, a riluzole derivative. Bioorg Med Chem. 1994 Aug;2(8):793-8.
59 Electrophysiologic effects of RS-2135, a new antiarrhythmic compound, on canine Purkinje fibers. J Cardiovasc Pharmacol. 1992 Dec;20(6):955-60.
60 WO patent application no. 2013,0439,25, Sodium channel blockers reduce glucagon secretion.
61 U-54494A: a unique anticonvulsant related to kappa opioid agonists. J Pharmacol Exp Ther. 1987 Nov;243(2):542-7.
62 Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
63 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
64 Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
65 Sodium channel binding and anticonvulsant activities for the enantiomers of a bicyclic 2,4-oxazolidinedione and monocyclic models. J Med Chem. 1989 Jul;32(7):1577-80.
66 Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
67 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15.
68 Effect of neurotoxins on the electrical activity and contraction of the heart muscle. C R Seances Soc Biol Fil. 1997;191(3):451-71.